Happy holidays from Crystec!

As 2021 comes to an end, we look back at some of the key highlights from an eventful year at Crystec.

A new research centre in Haimen, China

In the spring, we were pleased to share the news of Crystec’s new R&D facility in Haimen, China. The site was established as part of the Yangtze Delta Advanced Drug Development platform, which is dedicated to accelerating pharmaceutical product innovation underpinned by advanced pharmaceutical excipients and drug delivery technologies. Crystec’s mSAS® technology plays an important role in enabling the development of new therapeutics, the creation of value-added medicines, and in simplifying formulations and manufacturing processes.

Valued Collaborations

Crystec’s has a long-standing commitment to our valued global partners, and 2021 has been no exception. This year we were delighted to announce two new notable collaborations:

In August, SignalRx Pharmaceuticals, ADYA Consulting, and Crystec announced a collaboration to develop a dry powder inhaled formulation of SF2523 for the treatment of pulmonary fibrosis, lung cancer and SARS-CoV-2 related illnesses. 

 In October, Crystec announced a collaboration with Argentinian biotech company Biosidus, focused on facilitating nasal or inhaled delivery of biotherapeutics, eliminating the need for daily injections. Work is currently underway to develop a dry powder preparation of teriparatide for the treatment of osteoporosis.

A return to in-person conference

Crystec have continued to participate in online conferences throughout the pandemic, and they have served as a lifeline throughout the long months (and years) of worldwide restrictions. But the autumn brought a brief respite, and we were pleased to have the opportunity to attend our first face-to-face meetings in nearly two years. Particularly exciting was our trip to Milan for CPhI Worldwide, where we were able to meet with familiar and new faces.

We are thankful for the opportunities to connect with people across the world, and hope to see much more of you in 2022!

Happy Holidays!

We would like to take this opportunity to thank all of our collaborators, partners, clients, colleagues and valued friends for their continued support over the past year, and we look forward to celebrating your ongoing successes in 2022!

Warmest wishes,

Previous
Previous

mSAS® strategies for the development of natural products

Next
Next

Developing biological drugs for inhaled delivery